Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 plus toripalimab vs investigator's choice in platinum-failed recurrent/metastatic cervical cancer
CTR20260360Phase 3Active
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of WXFL10030390, toripalimab in cervical cancer (mCC), sponsored by Shanghai Jiatan Pharmatech. Started Jun 2026; status: active.
02
Drugs
WXFL10030390toripalimab
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on CTR20260360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260360.